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tion, drug cost, and therapeutic outcomes. Although
additional data is required for conclusive evidence, the
preliminary data suggests a downward trend in antibiotic
costs in the ICU.
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INTRODUCTION: The impact of prescription NSAIDS
on the GI tract is well documented. The easy availability
of low-dose OTC NSAIDs may lead to iatrogenic GI dis-
ease invisible to the medical community. OBJECTIVE:
To determine if the role and rate of GI adverse side ef-
fects were related to over-the-counter NSAID use. METH-
ODS: Data were obtained by structured telephone survey
administered to a nationally representative, randomly se-
lected US adult population (40 years). We compared re-
sponses of regular OTC NSAID users (defined as use for
at least 4 of 7 days, and 16 of 30 days prior to the sur-
vey) with those of non-users. Logistic regression com-
pared the likelihood of GI symptoms and use of GI med-
ications, after adjusting for age, gender, ethnicity, and
self-reported health status. RESULTS: We surveyed 535
OTC NSAID users (mean age  63, range 40–96) and
1068 non users (mean age  63, range 40–93). NSAID
users were 2.1 times more likely to report GI symptoms
than non users (P  0.0001), and 2.7 times more likely
to have taken OTC GI medications than non users (P 
0.0001) during past 30 days. 84.8% of NSAID users tak-
ing GI medications for their symptoms had not informed
a physician of GI symptoms. CONCLUSIONS: OTC
NSAIDs are widely used and thought to be safe at low
dose. Our data show users commonly experience GI
symptoms, for which they self-medicate without inform-
ing their physician. This may represent an important bur-
den of hidden GI disease.
PGD2
IMPROVED DRUG COMPLIANCE USING 
EDUCATION AFFECTS MEDICAL UTILIZATION 
AND QUALITY OF LIFE FOR PEPTIC ULCER 
DISEASE PATIENTS
Addiego J1, Berger J1, McStay P1, Craig R2, O’Leary W1, Slezak 
J1, Schwaab M1, Hasan E1, Apolinski L1
1Caremark, Northbrook, IL, USA; 2NUMS, Chicago, IL, USA
Peptic ulcers, erosions of the stomach lining, afflict greater
than 25 million Americans. Ulcers diminish quality of life
and cost nearly $6 billion dollars annually. OBJECTIVE:
To decrease unnecessary medical utilization, histamine-2-
blocker (H2) and proton-pump-inhibitor (PPI) utilization
and improve quality of life for peptic ulcer patients by us-
ing educational intervention to increase compliance to
drug regimens for H. pylori eradication. METHODS: Pa-
tients were targeted for specific antibiotic therapies via
drug data and verified at first telephone contact. A ques-
tionnaire developed and validated by Lewin-TAG was
used for data collection. Data were collected for a 90 day
period pre/post therapy regarding hospitalizations, doc-
tor visits, emergency room visits, lost productivity, out-
patient surgeries, pharmacy utilization and medical test/
procedures resulting from the disease. Quality of life
questions measured how often usual activities and work
productivity were reduced due to peptic ulcer disease. Pa-
tient satisfaction with the program was also measured.
RESULTS: (n  1993, response rate  94.5%) Patient
compliance to drug regimen was found to be 95.7%.
Hospitalizations were reduced by 73% (P  0.0001),
doctor visits by 49% (P  0.0001). Emergency room vis-
its were reduced by 72% (P  0.0001) and outpatient
surgeries by 56% (P  0.0001). Finally, a decrease of
54% in H2/PPI usage (P  0.0001) and a decrease of
76% in medical tests/procedures (P  0.0001) were seen.
Participants reported a 13% decrease in pain and symp-
toms (P  0.005) and a 34% increase in productivity
(P  0.0001). Participant satisfaction rate with the pro-
gram was 98.6%. CONCLUSION: The CarePatterns
peptic ulcer disease program improves patients’ quality
of life, reduces unnecessary medical and pharmacy utili-
zation, and is cost-effective.
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OBJECTIVE: The aim of this project is to evaluate the ef-
fectiveness of a program including practice guidelines,
treatment algorithms, and peer comparison feedback in
changing physicians’ prescribing behaviors in the treat-
ment of patients with peptic ulcer disease (PUD). METH-
ODS: A prospective intervention with a control group
was conducted to determine the impact of a PUD infor-
mation dissemination program targeted towards physi-
cians in a managed care setting. Pharmacy claims data
were used to assess impact of the program on utilization
of eradication therapy, long-term antisecretory utiliza-
tion, and total cost of drug therapy per patient. RE-
SULTS: Preliminary data from a 3-month follow-up pe-
riod are available and indicate that utilization of eradication
